Renal protection by low dose irbesartan in diabetic nephropathy is paralleled by a reduction of inflammation, not of endoplasmic reticulum stress  by Hartner, Andrea et al.
Biochimica et Biophysica Acta 1842 (2014) 558–565
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isRenal protection by low dose irbesartan in diabetic nephropathy is
paralleled by a reduction of inﬂammation, not of endoplasmic
reticulum stressAndrea Hartner a,⁎, Nada Cordasic b, Bernd Klanke b, Carlos Menendez-Castro a, Roland Veelken b,
Roland E. Schmieder b, Karl F. Hilgers b
a Department of Pediatrics and Adolescent Medicine, University of Erlangen–Nürnberg, Loschgestrasse 15, D-91054 Erlangen, Germany
b Department of Nephrology and Hypertension, University of Erlangen–Nürnberg, Loschgestrasse 8, D-91054 Erlangen, Germany⁎ Corresponding author at: Nephrology Laboratory
Erlangen, Germany. Tel.: +49 9131 8539200; fax: +49 9
E-mail address: andrea.hartner@uk-erlangen.de (A. H
0925-4439/$ – see front matter © 2014 Elsevier B.V. All r
http://dx.doi.org/10.1016/j.bbadis.2014.01.001a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 July 2013
Received in revised form 18 December 2013
Accepted 6 January 2014
Available online 10 January 2014
Keywords:
Diabetic nephropathy
Angiotensin receptor antagonist
Irbesartan
ER stress
InﬂammationDiabetes can disrupt endoplasmic reticulum (ER) homeostasis which leads to ER stress. ER stress-induced renal
apoptosis seems to be involved in the development of diabetic nephropathy. The present study was designed to
investigate the contribution of reduced ER stress to the beneﬁcial effects of an angiotensin receptor blocker.
Insulin-dependent diabetes mellitus was induced by streptozotocin injections to hypertensive mRen2-
transgenic rats. After 2 weeks animalswere treatedwith 0.7 mg/kg/day irbesartan. Blood glucose, blood pressure
and protein excretion were assessed. Expression of ER stress markers was measured by real-time PCR. Immuno-
histochemistry was performed to detect markers of ER stress, renal damage and inﬁltrating cells.
Glomerulosclerosis and apoptosis were evaluated. Diabetic mRen2-transgenic rats developed renal injury with
proteinuria, tubulointerstitial cell proliferation as well as glomerulosclerosis and podocyte injury. Moreover, an
increase in inﬂammation, podocyte ER stress and apoptosis was detected. Irbesartan somewhat lowered blood
pressure and reduced proteinuria, tubulointerstitial cell proliferation and glomerulosclerosis. Podocyte damage
was ameliorated but markers of ER stress (calnexin, grp78) and apoptosis were not reduced by irbesartan. On
the other hand, inﬂammatory cell inﬁltration in the tubulointerstitium and the glomerulus was signiﬁcantly at-
tenuated. We conclude that irbesartan reduced renal damage even in a very low dose. The beneﬁcial effects of
low dose irbesartan were paralleled by a reduction of blood pressure and inﬂammation but not by a reduction
of ER stress and apoptosis. Thus, sustained endoplasmic reticulum stress in the kidney does not necessarily
lead to increased inﬂammation and tubulointerstitial or glomerular injury.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
End stage renal failure is often a consequence of nephropathy devel-
oping in patients with diabetes mellitus [1]. Endoplasmic reticulum
stress is a typical feature of diabetic kidney disease [2]. The endoplasmic
reticulum is responsible for proper folding of secretory and membrane
proteins, which can be disturbed in conditions of nutrient deprivation,
oxidative stress and abnormal calcium levels in the endoplasmic reticu-
lum [2]. Accumulation of misfolded proteins leads to the unfolded
protein response, which includes an increased expression of endoplas-
mic chaperone proteins like glucose-regulated protein 78 (grp78) [3].
On the one hand, the endoplasmic reticulum stress-induced unfolding
protein response can help to restore endoplasmic reticulum homeosta-
sis and proper protein folding, while on the other hand sustained, Loschgestrasse 8, D-91054
131 85392021.
artner).
ights reserved.endoplasmic reticulum stress results in increased apoptosis, which
may contribute to organ damage [2,4].
In vitro studies in tubular epithelial cells revealed that albumin as
well as high glucose both induce endoplasmic reticulum stress and
thus might be causative for diabetic endoplasmic reticulum stress in
the diabetic kidney [5]. In addition to tubular cells, endoplasmic reticu-
lum stress was described also in glomerular cells of diabetic kidneys
[6,7]. Inhibition of the renin–angiotensin system with an ACE inhibitor
or the angiotensin receptor antagonist (AT1RA) olmesartan ameliorat-
ed renal tubular apoptosis and endoplasmic reticulum stress in
normotensive rats with experimental diabetes [8,9].
Diabetic nephropathy is frequently associated with hypertension in
humans [1]. Therefore, animal models were developed to mimic
human diabetic nephropathy in combining hyperglycemia and hyper-
tension. One of these models is the streptozotocin diabetic, mRen-2
transgenic hypertensive rat [10]. This model has the advantage of
leading to marked damage to kidney tissue although the pathogenesis
of this injury is complex, with high blood pressure per se playing an
important role [11,12]. On the other hand, a considerable part of the
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Administration of angiotensin receptor antagonists (AT1RA) proved to
be beneﬁcial to attenuate diabetic nephropathy in hypertensive as
well as normotensive models of diabetes mellitus [13–17]. The AT1RA
irbesartan was used in doses from 5 to 65 mg/kg/day to ameliorate
murine diabetic renal injury [17–19]. We aimed to attenuate diabetic
nephropathy by suppressing diabetes-induced endoplasmic reticulum
stress and renal apoptosis using a very low, non-hypotensive dose of
irbesartan (0.7 mg/kg/day).
2. Material and methods
2.1. Rat model of diabetic nephropathy
Rats were housed in a room maintained at 22 ± 2 °C, exposed to a
12 hour dark/light cycle. The animals were allowed unlimited access
to chow (#1320, Altromin, Lage, Germany) and tap water. EU Directive
2010/63/EU for animal experiments was followed. All procedures
performed on animals were done in accordance with guidelines of the
American Physiological Society and were approved by the local govern-
ment authorities (Regierung von Mittelfranken, AZ # 621-2531.31-19/
96). 20 male rats heterozygous for the mouse ren-2 transgene (TGR)
with angiotensin II dependent hypertension [15] at an average body
weight of 250 g were used for induction of diabetes by intraperitoneal
injection of streptozotocin (STZ) (Sigma, Deisenhofen, Germany)
(70 mg per kg of body weight) dissolved in 0.1 M sodium citrate buffer
(pH 4.5) at the age of 12 weeks. 6 age-matched Sprague–Dawley–
Hannover (SD) served as controls (Möllegaard, Eijby, Denmark).
Two days later, blood was obtained from the tail vein and diabetes
was conﬁrmed by measurement of blood glucose using a reﬂectance
meter (Glucometer Elite II, Bayer, Leverkusen, Germany). Only rats
with a consistent blood glucose N 250 mg/dL were included (16
TGR and 6 SD). In 8 TGR-STZ, a low dose of irbesartan (0.7 mg/kg
body weight/day; Sanoﬁ-Aventis, Frankfurt, Germany) was adminis-
tered 1 week after STZ injection for 4 weeks. The animals received
osmotic minipumps (Alzet model 2004; Alza Scientiﬁc Products, Palo
Alto, CA, USA) intraperitoneally, which delivered 0.25 μL/h for
28 days. All groups were followed for 5 weeks. Blood glucose and sys-
tolic blood pressure (as measured by tail-cuff plethysmography under
light ether anesthesia) were monitored weekly (at 8 a.m.). At the end
of the experiment, the rats were kept in metabolic cages to collect
urine for 24 h. Subsequently, the rats were equipped with a femoral
catheter under light isoﬂurane anesthesia and arterial blood pressure
was measured in conscious rats via transducers (Grass Instruments,
Quincy, USA) connected to a polygraph (Hellige, Freiburg, Germany)
4 h after termination of anesthesia. Urinary protein and serum glucose
were analyzed with the automatic analyzer Integra 800 (Roche
Diagnostics, Mannheim, Germany). Rats were sacriﬁced and kidneys
were weighed and decapsulated. Renal tissue was ﬁxed in methyl-
Carnoy solution (60% methanol, 30% chloroform and 10% glacial acetic
acid) for histology and immunohistochemistry. Cortical tissue was
snap frozen in liquid nitrogen and processed for RNA analysis.
2.2. Real-time RT-PCR
Renal tissue was homogenized in 500 μL of RLT buffer reagent
(Qiagen, Hilden, Germany) with an ULTRA-TURRAX for 30 s and total
RNA was extracted from homogenates with RNeasy Mini columns
(Qiagen) according to the standard protocol. First-strand cDNA was
synthesized with TaqMan reverse transcription reagents (Applied
Biosystems, Darmstadt, Germany) using random hexamers as primers.
Final RNA concentration in the reaction mixture was adjusted to
0.1 ng/μL. Reactions without Multiscribe reverse transcriptase were
used as negative controls for genomic DNA contamination. RT-products
were diluted 1:1 with dH2O before PCR procedure. PCR was performed
with an ABI PRISM 7000 Sequence Detector System and SYBR Green orTaqMan reagents (Applied Biosystems) according to the manufacturers'
instructions. All samples were run in triplicate. Speciﬁc mRNA levels
were calculated and normalized to 18S rRNA as a housekeeping
gene with the ΔΔCT method as speciﬁed by the manufacturer (http://
www3.appliedbiosystems.com/cms/groups/mcb_support/documents/
generaldocuments/cms_040980.pdf). Primer Express software
(PerkinElmer, Foster City, CA)was used to design primer pairs. For detec-
tion of Bcl-2, the forward primer was 5′-GATGACTGAGTACCTGAACC-3′;
the reverse primer was 5′-CCATATAGTTCCACAAAGGCAT-3′. For the de-
tection of the housekeeping gene 18S, the forward primer was 5′-TTGA
TTAAGTCCCTGCCCTTTGT-3′; the reverse primer was 5′-CGATCCGAGG
GCCTCACTA-3′.
2.3. Renal histology and immunohistochemistry
After overnight ﬁxation in methyl-Carnoy solution, tissues were
dehydrated by bathing in increasing concentrations of methanol,
followed by 100% iso-propanol. After embedding in parafﬁn, 3 μm sec-
tions were cut with a Leitz SM 2000 R microtome (Leica Instruments,
Nussloch, Germany). After deparafﬁnization, endogenous peroxidase
activitywas blockedwith 3%H2O2 inmethanol for 20 min at room tem-
perature. A mouse monoclonal antibody detecting proliferating cells
(PCNA) was purchased from Santa Cruz Biotechnologies (Heidelberg,
Germany) and used at a dilution of 1:50. The mouse monoclonal anti-
body against desmin was purchased from DAKO (Hamburg, Germany)
and used at a dilution of 1:50. The mouse monoclonal antibody against
synaptopodinwas fromProgen (Heidelberg, Germany) and used at a di-
lution of 1:100. The rabbit polyclonal antibody to WT-1 was from
NeoMarkers (Fremont, CA, USA) and used at a dilution of 1:50. The rab-
bit polyclonal antibody to phosphorylated SMAD2/3 was from Santa
Cruz Biotechnologies and used at a dilution of 1:5000. The rabbit poly-
clonal antibodies against calnexin and grp78 both were from Abcam
(Cambridge, UK) and used at a dilution of 1:100. Themousemonoclonal
antibody against the macrophage marker ED-1 was from Serotec
(Biozol, Eching, Germany) and used at a dilution of 1:250. The mouse
monoclonal antibody against the pan leukocyte marker CD45 was
from BD Pharmingen (Heidelberg, Germany) and used at a dilution of
1:100. The rabbit polyclonal antibody against osteopontin was used as
described before [20].
Intraglomerular ED-1 andWT-1 positive cells were counted in every
third glomerulus of a given kidney section (no selection) and expressed
as cells per glomerular section. Glomerular pSMAD2/3 positive cells
were evaluated as described [21]. Interstitial PCNA, CD45 or ED-1 posi-
tive cells were counted in 30 medium-power (magniﬁcation 250×)
cortical views per section. Counting was started in a random cortical
ﬁeld and in consecutive non-overlapping cortical ﬁelds to the right
of the previous view without selection; if necessary, counting was
continued at the opposite (left) edge of the section. Glomerular desmin,
synaptopodin, calnexin and grp78 stainings were measured by
Metaview software (Visitron Systems, Puchheim, Germany) in every
third glomerulus per cross section, and the stained area was expressed
as percentage of the total area of the glomerular tuft. Tubulointerstitial
calnexin and osteopontin stainings were measured by Metaview
software in 30 medium-power (magniﬁcation 250×) cortical views
per section, and the stained area was expressed as percentage of the
total area of the cortical view.
The kit to detect apoptotic cells (TACS 2 TdT Blue Label in situ
Apoptosis Detection Kit) was from Trevigen (Biozol, Eching, Germany)
and used according to the manufacturer's instructions. For analysis of
glomerulosclerosis, 2 μm thick deparafﬁnized sections were stained
with periodic acid-Schiff (PAS) and then evaluated on 50 consecutive
glomeruli using a ×40 objective. A score from 0 (no sclerosis) to 4
(N75% sclerosis) was applied. Tubulointerstitial damage was assessed
in 10 non-overlapping medium power randomly sampled views per
PAS-stained kidney section using a tubulointerstitial damage score
grading tubular atrophy, tubular dilatation, interstitial ﬁbrosis and
Fig. 1. Systolic blood pressuremeasurements as assessed by tail cuff plethysmography (A).
Time points ofmeasurementwere−4, 4 days before start of irbesartan treatment; 3, 9, 16
and 24 days after start of irbesartan treatment. Mean arterial blood pressure measured
intraarterially (B). Co, control rats; DM, diabetic TGR; DM + AT1RA, irbesartan-treated di-
abetic TGR. Data are mean ± SEM. * indicates p b 0.05 versus control rats, # indicates
p b 0.05 versus respective untreated diabetic TGR group.
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involving less than 25% of the area; grade 2, lesions affecting 25–50%;
grade 3, lesions involvingmore than 50% and grade 4 involving (almost)
the entire area. All histological evaluations were performed in a blinded
fashion.
2.4. Analysis of data
One-way analysis of variance, followed by post-hoc LSD test, was
used to compare groups. A p value b 0.05 was considered signiﬁcant.
The procedures were carried out using the SPSS version 19 software
(IBM, Ehningen, Germany). Values are displayed as means ± standard
error of the mean.
3. Results
3.1. Effect of low dose irbesartan on blood glucose and blood pressure
Induction of diabetes in TGR led to a reduction in bodyweight,which
was not restored by treatment with low dose irbesartan (Table 1).
Relative kidneyweights were increased in all diabetic groups to a similar
degree, irrespective of the treatment (Table 1). Relative left ventricular
weights increased in diabetic nephropathy andwere not signiﬁcantly re-
duced by irbesartan (Table 1). Blood glucose values were signiﬁcantly
higher in diabetic animals and even tended to be increased more prom-
inently after irbesartan treatment (Table 1). Systolic blood pressure
measurements using tail cuff plethysmography conﬁrmed hypertension
in diabetic TGR, but no signiﬁcant reduction of blood pressure was
observed after irbesartan treatment (Fig. 1A). Mean blood pressure was
increased in diabetic TGR. Low dose irbesartan surprisingly somewhat
reduced mean arterial blood pressure (Fig. 1B), if measured
intraarterially.
3.2. Low dose irbesartan has a beneﬁcial effect on diabetes-induced renal
injury
Protein excretion as well as albumin excretion was augmented in
diabetic TGR and tended to be lower after irbesartan treatment
(Table 1). Indices for glomerular and tubular damage as measured
using a glomerulosclerosis score and a tubulointerstitial lesion score,
were increased in diabetic TGR and signiﬁcantly reduced by irbesartan
treatment (Table 1). Tubulointerstitial damage was conﬁrmed by
evaluating tubulointerstitial cell proliferation. Cell proliferation was in-
creased in the renal tubulointerstitium of diabetic TGR and signiﬁcantly
reduced by irbesartan treatment (Fig. 2A). Glomerular damage was also
assessed by evaluating a marker of functional podocytes, synaptopodin,
which is reduced in the glomeruli of diabetic TGR. Irbesartan treatment
increased glomerular synaptopodin immunoreactivity in these animals
(Fig. 2B). Desmin as a marker of podocyte damage on the other hand
was signiﬁcantly increased in glomeruli of diabetic TGR and was re-
duced by irbesartan treatment (Fig. 2C and D). The number of WT-1Table 1
Auxiliary data and markers of renal damage.
Experimental group Co
Body weight (g) 420.8 ± 8.8
Relative kidney weight (mg/g) 6.36 ± 0.14
Relative left ventricular weight (mg/g) 2.24 ± 0.06
Serum glucose (mg/dL) 94.57 ± 2.49
Albumin excretion (mg/24 h) 8.11 ± 3.26
Protein excretion (mg/24 h) 24.30 ± 4.53
Glomerulosclerosis index 0.10 ± 0.01
Tubulointerstitial lesion score 0.13 ± 0.03
Number of glomerular cells/cross section 45.51 ± 0.66
Co, control rats; DM, diabetic TGR; DM + AT1RA, irbesartan-treated diabetic TGR. Data are me
⁎ p b 0.05 DM versus co.
# p b 0.05 DM + AT1RA versus DM.positive well differentiated podocytes was reduced in diabetic TGR,
while irbesartan treatment increased the number of WT-1 positive
podocytes (Fig. 3). The total number of glomerular cells was increased
in diabetic TGR. Irbesartan did not inﬂuence glomerular cell number
(Table 1).
3.3. Low dose irbesartan has no inﬂuence on diabetes-induced endoplasmic
reticulum stress or activation of the SMAD pathway
Two markers of endoplasmic reticulum stress were quantiﬁed:
Calnexin immunoreactivity was increased in the renal tubulointerstitium
and in the glomerulus of diabetic TGR. Irbesartan treatment did not atten-
uate this increase (Fig. 4A+B). Similarly, glomerular grp78 staining was
augmented in diabetic TGR, but not signiﬁcantly altered by irbesartan
(Fig. 4C). Both glomerular calnexin and grp78 immunohistochemistryDM DM + AT1RA
309.3 ± 21.5⁎ 260.3 ± 12.5#
9.61 ± 0.55⁎ 10.22 ± 0.25
2.59 ± 0.08⁎ 2.45 ± 0.06
296.25 ± 33.63⁎ 372.89 ± 12.24
65.91 ± 21.08⁎ 34.19 ± 13.77
81.62 ± 28.10⁎ 43.53 ± 9.84
0.57 ± 0.19⁎ 0.25 ± 0.06#
1.56 ± 0.12⁎ 0.49 ± 0.05#
50.26 ± 0.85⁎ 49.60 ± 1.78
ans ± SEM.
Fig. 2. Tubulointerstitial (TI) cell proliferation (panel A), glomerular synaptopodin staining
(panel B) and glomerular desmin staining (panel C). Panel D shows exemplary photomi-
crographs of desmin stained glomeruli. Co, control rats; DM, diabetic TGR; DM + AT1RA,
irbesartan-treated diabetic TGR. Data aremean ± SEM. * indicates p b 0.05 versus control
rats, # indicates p b 0.05 versus respective untreated diabetic TGR group.
Fig. 3. Glomerular WT-1 positive podocytes with exemplary photomicrographs of WT-1
stained glomeruli. Co, control rats; DM, diabetic TGR;DM + AT1RA, irbesartan-treated di-
abetic TGR. Data are mean ± SEM. * indicates p b 0.05 versus control rats, # indicates
p b 0.05 versus respective untreated diabetic TGR group.
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mic reticulum stress, apoptosis is induced frequently. Apoptotic cells
were more frequent in the tubulointerstitium and the glomeruli of
diabetic TGR. Irbesartan treatment had no inﬂuence on the number of ap-
optotic cells in diabetic kidneys (Fig. 5A+B). Moreover, the expression of
the antiapoptotic protein Bcl-2 was reduced in the kidney of diabetic TGRwith or without treatment with irbesartan to a similar degree
(0.45 ± 0.11 in diabetic TGR and 0.37 ± 0.06 in irbesartan-treated
diabetic TGR versus 1.00 ± 0.42 in control rats, p b 0.05 versus control).
Increased TGF-β activity can also contribute to glomerular damage in di-
abetic nephropathy, e.g. mediate apoptosis. Therefore, staining for the
phosphorylated form of the TGF-β signaling molecules SMAD2/3 was
performed. An increased number of phospho-SMAD positive glomerular
cellswere detected in diabetic TGR, but irbesartan treatment hadno inﬂu-
ence on the number of phospho-SMAD positive cells (Fig. 6).
3.4. Low dose irbesartan has a beneﬁcial effect on diabetes-induced renal
inﬂammation
The number of leukocytes in the tubulointerstitium of diabetic TGR
was signiﬁcantly increased. This increase was attenuated by irbesartan
treatment (Figs. 7A+8). Tubulointerstitial staining of the macrophage
chemoattractant osteopontin was more expanded in the kidneys of dia-
betic TGR and reduced by irbesartan treatment (Figs. 7B + 8). The num-
ber of inﬁltrated macrophages was increased in the tubulointerstitium
and in the glomeruli of diabetic TGR. Irbesartan treatment reduced the
number of renal macrophages to control levels (Figs. 7C + 8).
4. Discussion
Our results show that in a rat model of diabetic nephropathy associ-
ated with increased blood pressure tubulointerstitial and glomerular
damage is induced. A low dose of AT1RA irbesartan signiﬁcantly reduced
tubulointerstitial and glomerular damage and ameliorated the loss of
differentiated podocytes. This was paralleled by a signiﬁcant reduction
of diabetes-induced renal inﬂammation. Markers of endoplasmic reticu-
lum stress, activation of the SMAD pathway as well as apoptosis were
increased in diabetic kidneys. Neither endoplasmic reticulum stress,
nor SMAD activation or apoptosis were attenuated by low dose
irbesartan, supporting the notion that treatment with irbesartan could
have beneﬁcial effects on diabetic nephropathy via reduction of inﬂam-
mation, but not via reduction of endoplasmic reticulum stress or TGF-β
induced SMAD activity.
A prominent feature of diabetic nephropathy is the induction of
endoplasmic reticulum stress leading to the unfolded protein response
Fig. 4. Tubulointerstitial (TI) calnexin staining (panel A), glomerular calnexin staining
(panel B) and glomerular grp78 staining (panel C). Panel D shows exemplary photo-
micrographs of calnexin or grp78 stained glomeruli. Co, control rats; DM, diabetic
TGR; DM + AT1RA, irbesartan-treated diabetic TGR. Data are mean ± SEM. * indicates
p b 0.05 versus control rats.
Fig. 5. Tubulointerstitial (TI) apoptotic cells (panel A) and glomerular apoptotic cells
(panel B). Panel C shows exemplary photomicrographs of tubulointerstitial or glomerular
apoptotic cells (arrows). Co, control rats; DM, diabetic TGR; DM + AT1RA, irbesartan-
treated diabetic TGR. Data are mean ± SEM. * indicates p b 0.05 versus control rats.
562 A. Hartner et al. / Biochimica et Biophysica Acta 1842 (2014) 558–565in the tubulointerstitium but also in glomeruli of the diabetic kidney
[6,7]. Studies in cultured renal tubular epithelial cells suggest that
hyperglycemiamight directly cause an induction of endoplasmic reticu-
lum stress in cells [5]. This results in an unfolded protein response,
characterized by the induction of chaperone proteins which help to
enable proper protein folding, like grp78 which was described to beupregulated in diabetic nephropathy [2,6]. Sustained endoplasmic retic-
ulum stress, however, will trigger apoptosis of affected cells and thus
promote diabetic nephropathy [6]. In this context we investigated the
expression of the chaperones grp78 and calnexin, which are both
induced in response to endoplasmic reticulum stress [22,23] and there-
fore are used as markers for the degree of endoplasmic reticulum stress
in our diabetic model. Surprisingly, treatment with irbesartan, though
beneﬁcial in alleviating diabetic nephropathy, did not have any effects
on the degree of endoplasmic reticulum stress or subsequent apoptosis,
arguing against a decisive role of a reduction of endoplasmic reticulum
stress in the attenuation of diabetic nephropathy. Our data contrastwith
the results of others [8,9] which reported a reduction of ER stress and
apoptosis in diabetic rats treated with an angiotensin converting
enzyme inhibitor [9] or an angiotensin II receptor antagonist [8].
These discrepant ﬁndings cannot be explained by the somewhat differ-
ent sets of markers used for ER stress, as the results on apoptosis are
equally different. However, we assume that the comparatively higher
doses of antagonists used in these studies [8,9] may account for the dif-
ferent ﬁndings. We do not claim to show that angiotensin II antagonist
cannot ameliorate ER stress but rather wish to point out that a very low
Fig. 6. Glomerular SMAD activation as assessed by counting phospho-SMAD positive
glomerular cells with exemplary photomicrographs of phospho-SMAD stained glomeruli.
Co, control rats; DM, diabetic TGR; DM + AT1RA, irbesartan-treated diabetic TGR. Data
are mean ± SEM. * indicates p b 0.05 versus control rats.
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theless ameliorated inﬂammation and kidney injury.
Most strikingly, the reduction of podocyte damage by irbesartan, as
revealed by the restoring of synaptopodin and WT-1 staining and the
decrease of podocytic desmin staining did not coincide with changes
in podocytic grp78 or calnexin immunoreactivity. We did not evaluate
the total number of podocytes and thus cannot exclude that the reduc-
tion of WT-1 positive cells is due to podocyte loss instead of podocyteFig. 7. Tubulointerstitial (TI) CD45-positive leukocyte inﬁltration (panel A), osteopontin staini
phage inﬁltration (panel D). Co, control rats; DM, diabetic TGR; DM + AT1RA, irbesartan-treate
p b 0.05 versus respective untreated diabetic TGR group.dedifferentiation. But at least it is conceivable that a reduction of fully
differentiated and functional podocytes is observed in diabetic
nephropathy and that this is ameliorated by low dose irbesartan. Diabe-
tes led to hypercellularity of glomeruli and this was not modiﬁed by
irbesartan. We did not study glomerular number and thus do not
know if our model of diabetic nephropathy leads to a loss of glomeruli.
However, we consider this unlikely, as we did not observe severe
glomerulosclerotic changes or collapsing glomerulopathy which might
lead to a complete loss of glomerular function in our model. Moreover,
data from literature do not support the notion that experimental
diabetes might result in alterations in the number of glomeruli [24].
TGF-β is also an important mediator of glomerular damage in
diabetic nephropathy [25] and is known to confer apoptosis of glomer-
ular cells [26]. Moreover, it has been shown that inhibition of the renin–
angiotensin system in experimental diabetic nephropathy using AT1RA
in higher doses downregulates renal TGF-β [14]. Therefore, we studied
the effects of irbesartan treatment on TGF-β mediated SMAD 2/3
phosphorylation. Our data show that SMAD activity was increased in
glomeruli of animals with diabetic nephropathy. However, low dose
irbesartan did not reduce SMAD phosphorylation although glomerular
damage was clearly ameliorated. Thus, the protective effect of
irbesartan in our model of diabetic nephropathy is not mediated by
reduced SMAD activation. This, however, does not necessarily preclude
an effect of reduced TGF-β action, because TGF-β action can also be
mediated by SMAD independent signaling [27].
AT1RA was beneﬁcial in treating diabetic nephropathy in animal
models and in diabetic patients, even in situations where diabetes is
not associated with hypertension [15,17,28,29]. We chose a dose of
irbesartan,which is an order ofmagnitude lower than the onedescribed
in several models of hypertension to only marginally lower blood pres-
sure [30,31]. Nevertheless, there was a certain degree of blood pressure
lowering, at least whenmeasured intraarterially. In previous studies the
streptozotocin diabetic, mRen-2 transgenic hypertensive rat proved to
bemarkedly susceptible even to low doses of AT1RA [11]. Thus, we can-
not exclude that the protective effect of irbesartan on renal damage inng (panel B), tubulointerstitial macrophage inﬁltration (panel C) and glomerular macro-
d diabetic TGR. Data are mean ± SEM. * indicates p b 0.05 versus control rats, # indicates
Fig. 8. Exemplary photomicrographs of immunohistochemical stainings for CD45, osteopontin (OPN) and ED1 in control rats (co); diabetic TGR (DM); and irbesartan-treated diabetic TGR
(DM + AT1RA).
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intraglomerular blood pressure rather than of a reduction of the sequel-
ae of diabetes. In particular it has been shown that blood pressure low-
ering can reduce inﬂammatory markers in the kidney [32]. This is
further supported by the fact that endoplasmic reticulum stress, which
is a typical feature of diabetic nephropathy [2], not of hypertensive ne-
phropathy, is not attenuated by irbesartan. However, some of the
markers of renal injury in the streptozotocin diabetic,mRen-2 transgen-
ic hypertensive rat were shown to be dependent on diabetic injury [33],
like glomerular podocyte damage, which is also considerably ameliorat-
ed by low dose irbesartan. Future studies will be necessary to fully ex-
clude that the beneﬁcial effects of low dose irbesartan are effects of a
reduction in blood pressure.
Diabetic nephropathy is accompanied by renal tubular and glomerular
inﬂammation in human diabetes as well as normotensive and hyperten-
sive animal models of diabetic disease [34–37]. This was conﬁrmed by
previous own investigations [11,33] and in the present study, showing in-
creased tubulointerstitial and glomerular leukocyte inﬁltration in the
streptozotocin diabetic, mRen-2 transgenic hypertensive rat. Leukocyte
recruitment is pathogenetically linked to diabetic nephropathy and anti-
inﬂammatory treatment reduces diabetic renal injury [34–37]. AT1RA
are known to exert anti-inﬂammatory effects in various models of renal
disease [38,39]. Therefore, it seems conceivable that treatment with
irbesartan can effectively attenuate immune cell inﬁltration and the ex-
pression of osteopontin, which is known to act as a chemoattractant for
macrophages [40]. This seems to be independent from a reduction of
endoplasmic reticulum stress, although in different settings endoplasmic
reticulum stress is able to induce an inﬂammatory response [41].
5. Conclusion
Diabetic nephropathy in mRen-2 transgenic rats is attenuated by
low dose irbesartan. This is linked to a reduction of inﬂammation, notto a reduction of endoplasmic reticulum stress or TGF-β mediated
SMAD activity. We conclude that low dose irbesartan in this model
of diabetic nephropathy exerts its beneﬁcial effects via anti-
inﬂammatory properties. Although irbesartan was not effective in re-
ducing endoplasmic reticulum stress and apoptosis, amelioration of
renal damage was observed. Thus, sustained endoplasmic reticulum
stress in the kidney does not necessarily lead to increased inﬂammation
and tubulointerstitial or glomerular injury.
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